New addition over at Zenith Epigenetics.
New CEO continues to hire people she has worked with in the past.
Joy Zhu, M.D., Ph.D.Chief Medical Officer
Joy Zhu, M.D., Ph.D., joined Zenith Epigenetics Corp as the Chief Medical Officer in September 2014. Dr. Zhu has over 20 years of clinical development experience with a strong focus in oncology and has led the design and execution of multiple clinical trials of important novel investigational drugs like tyrosine kinase inhibitors (SUTENTâ), rank ligand antibody (XGEVA), PEGylated Recombinant Human Hyaluronidase (PEGPH20) and other mechanistically innovative drugs including HDAC and JAK inhibitors.
Joy began her career at CIBA Vision/Novartis Ophthalmic Unit in 1994 where she worked on two New Drug Applications, which led the FDA approvals of Zaditorâ and Resculaâ. While working as the Director of Clinical Development at SUGEN, Joy made significant contributions to the approval of SUTENTâ. At Amgen, Joy served as the Global Development Leader and led the Denosumab oncology clinical program, which included phase 1 through phase 3 studies in multiple indications and ultimately to the approval of XGEVA™. Joy was the Sr. VP of Global Clinical Development at S*BIO Pte Ltd from 2006 to 2011 where she built the development organization and was responsible for all development activities. Most recently, Joy was the VP of Oncology Development at Halozyme Therapeutics, where she oversaw the strategic and operational aspects of the oncology drug development programs.